Across TCGA pan-cancer cohorts, GPATCH8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GPATCH8 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPATCH8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPATCH8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where GPATCH8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.628	0.904	<.001	44	view →
LUAD	OS	Tertile	II,III,IV	0.811	0.410	.014	14	view →
PDAC	OS	Tertile	IV	0.973	0.540	.017	6	view →
CCRCC	DFS	Median	All	0.532	0.891	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GPATCH8 tumor-vs-normal RNA expression · all GPATCH8 data types